Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Guimard

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Plos One|August 4, 2022
Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trialAlexandra Audemard-Verger, Amélie Le Gouge, Vincent Pestre, et al.
The Lancet. Infectious Diseases|January 20, 2024
Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trialAchim J Kaasch, Luis Eduardo López-Cortés, Jesús Rodríguez-Baño, et al.
Antimicrobial Resistance and Infection Control|September 19, 2023
Staphylococcus aureus surgical site infection rates in 5 European countriesSibylle C Mellinghoff, Caroline Bruns, Markus Albertsmeier, et al.
Eclinicalmedicine|March 28, 2024
Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trialSuzana Margareth Lobo, Gaétan Plantefève, Girish Nair, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Plos One|August 4, 2022
Efficacy and safety of anakinra in adults presenting deteriorating respiratory symptoms from COVID-19: A randomized controlled trialAlexandra Audemard-Verger, Amélie Le Gouge, Vincent Pestre, et al.
The Lancet. Infectious Diseases|January 20, 2024
Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trialAchim J Kaasch, Luis Eduardo López-Cortés, Jesús Rodríguez-Baño, et al.
Antimicrobial Resistance and Infection Control|September 19, 2023
Staphylococcus aureus surgical site infection rates in 5 European countriesSibylle C Mellinghoff, Caroline Bruns, Markus Albertsmeier, et al.
Eclinicalmedicine|March 28, 2024
Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trialSuzana Margareth Lobo, Gaétan Plantefève, Girish Nair, et al.
Pageof 3